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Introduction
During the last decade, prostate cancer has become the
most common malignancy in men in the United States,
and in Germany it is already the second most common
malignant tumour diagnosed in men. This absolute and
relative increase in the incidence of prostate cancer in the
developed industrialized nations is due to several factors.
First, a still rising life expectancy and an already high
prevalence of latent prostate cancer in the elderly popula-
tion lead to a growing population of relatively healthy
septuagenarians and even octogenarians who live long
enough to experience prostate cancer.
Secondly, the diagnosis of prostate cancer has been
greatly improved by the usage of prostate-specific antigen
(PSA) and ultrasound-guided prostate biopsies. The wide-
spread use of these two tools in addition to the traditional
doctor’s palpating finger has brought an absolute increase
in the incidence of prostate cancer in many countries
where medical services are easily available. PSA and
prostate biopsies have also led to a diagnostic shift
towards the earlier diagnosis of more organ-confined
stages in younger patients.
It is clear that organ-confined tumours in relatively
young patients in their sixties or even fifties should be
aggressively treated. Due to the advances which radical
surgery has made, radical prostatectomy is today the first-
line treatment option for most patients in this age group.
However, the older age group will not necessarily be can-
didates for radical prostatectomy. Radiotherapy as an
alternative to radical surgery has always been advocated
as a less invasive, more easily tolerated treatment for
prostate cancer. However, percutaneous external beam
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radiotherapy (EBRT) has by necessity side effects and
complications arising from radiation to the organs and tis-
su s surrounding the prostate which can be bothersome.
For this reason the concept of trying to focus radiation
 the prostate as much as possible in order to reduce the
radiation dose delivered to the bladder, the urethra and the
rectum has long been a major concern for radiotherapists.
Three-dimensional conformal planning and oscillating
radiation fields have been improvements in EBRT which
address just this issue.
Brachytherapy
Another way to achieve maximum radiation focussing
on the prostate is interstitial radiotherapy (brachytherapy).
With brachytherapy, radioactive particles (seeds) are
brought into the target organ or tissue thus bringing the
radiation source directly into the tissue. Implantation can
be temporary or permanent, and organs which lie relative-
ly superficial to the body surface are amenable to intersti-
tial radiotherapy (uterine cervix, breast, head and neck
tumours). The use of brachytherapy dates back to the
beginning of this century when soon after the discovery of
radioactivity, radioactive materials and their potential uses
were introduced into clinical medicine.
Thus, brachytherapy as a treatment for prostate cancer
began in 1911 when Pasteau described the implantation of
radium isotopes using a transurethral catheter. In 1922,
Denning published the results of 100 patients with
prostate cancer treated by this method. However, results
were not satisfactory, and this treatment modality was not
developed further at the time.
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the 1950s when gold isotopes became readily available
[1]. The implantation technique before the era of ultra-
sonography remained a problem, and in the 1970s the
open surgical implantation of 125I seeds using the retropu-
bic access was used by Hilaris et al. [2]. However,
transurethral seed dislocation and lack of control of seed
positioning remained problematic issues with this method
and the rate of tumour control with ‘hot’ and ‘cold’ spots
in the prostate was disappointing [3, 4]. Long-term fol-
low-up of patients treated by this method showed disap-
pointing 10-year survival rates [5] and revealed that the
only significant prognostic factor which could be identi-
fied was the absence or presence of lymph node metas-
tases at the time of treatment. The therapeutic benefit of
this technique was therefore disnounced by Whitmore and
co-workers [6] in 1982.
Today we experience another renaissance of brachy-
therapy for prostate cancer. There are several reasons for
this. First, with the epidemiological shift in the age struc-
ture of our populations and the increased incidence of
prostate cancer brought about by advances in clinical
urology, we are today faced with a larger than ever num-
ber of prostate cancer patients who need and want treat-
ment. However, a significant proportion of these are not
good candidates for surgery and also, an increasing num-
ber of patients opt for minimally invasive treatment.
Secondly, the radioactive seeds which are today commer-
cially available have better radiation characteristics in
terms of radiation dose and half-lives. Thirdly, modern
imaging techniques allow precise pretreatment dosimetry,
better seed positioning and posttreatment dosimetry eval-
uation. All this was not possible before the use of high-
quality transrectal ultrasound and computerized tomog-
raphy. With these new possibilities several problems
encountered with the method in the past, such as ‘strand-
ed seeds’ [4], can be expected to have been solved and
modern brachytherapy for prostate cancer may well have
to offer advantages to patients and urologists.
Technique of Prostate Brachytherapy
Modern brachytherapy depends on the use of trans-
rectal ultrasonography, computerized dosimetry planning
systems and application devices (templates) which can be
fixed in a stable position relative to the perineum.
Two principally different approaches to brachytherapy
of the prostate are possible: permanent seed implantation
using isotopes with low energy and short half-lives
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(125I,198Au, 103Pd) [7] or the temporary afterloading tech-
nique (192Ir) whereby radioactive sources placed on nee-
dles are brought into the prostate for a short period and
removed thereafter. The afterloading technique is usually
applied in combination with EBRT and requires the tech-
nical installations of great sophistication and costs needed
for intraoperative radiotherapy application.
Permanent seed implantation is technically much easi-
er to implement and perform and therefore receives most
interest at present. Holm [8] described a technique of 
transrectal ultrasound-guided perineal implantation of 125I
s eds in 1983. This technique has become the standard
approach although several modifications and refinements
have been described by several other groups [9–11].
103Pd has become commercially available as an im-
plantable isotope seed since 1988 and since that time has
been used for prostate brachytherapy by several North
American radiotherapy centres [12]. 103Pd has a mean
half-life of 17 days with a mean energy of 21 keV, corre-
sponding to an initial radiation dose of 20–30 cGy. In
comparison, 125I has a half-life of 60 days, a mean energy
of 28 keV and an initial dose rate of 5–10 cGy. The advan-
tage of 103Pd is therefore that it can deliver a higher ener-
gy dose per volume with a shorter half-life.
The technique of permanent seed implantation into the
prostate depends on three main elements: conformal dosi-
metric planning based on high-quality imaging using CAT
scanning or transrectal ultrasound, real-time image-con-
trolled anatomical seed implantation based on transrectal
ultrasound or fluoroscopy and posttreatment dosimetric
control of seed positioning again using CAT scans. There
are only minor variations between the techniques used by
different institutions.
The exact pretreatment planning requires the comput-
erized anatomical measurement of the volumes of the
prostate, the urethra and the rectum in order to determine
the correct target radiation doses. These lie around
140–160 Gy for monobrachytherapy with 125I and around
115–120 Gy with 103Pd [13]. If brachytherapy is used in
conjunction with EBRT, much lower doses are required.
The perineal templates used for needle positioning limit
the distance between the needles to a minimum of 0.5 cm.
Usually a minimum of 1 cm is observed.
There is no agreement between different institutions
about the distribution of the total radiation dose within the
prostate. Some prefer a homogeneous dose distribution
with only 10–15% of the total dose applied to the periph-
ery of the prostate thus minimizing the radiation dose
which is delivered to the rectum and the urethra [14, 15].
Others prefer to apply 70% of the total dose to the prosta-
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tic periphery where most carcinomas arise, taking into
account that more radiation dose will be delivered to the
rectum [11, 16].
One problem of this mode of brachytherapy is that the
actually administered radiation dose is still variable
despite the use of real-time imaging and dosimetry. With
a target dose of 140–160 Gy, posttreatment dosimetry
evaluation can show variations from 30 to 260 Gy [17].
This will have obvious implications for the therapeutic
efficacy as does the problem of stranded seeds encoun-
tered with this technique. Possibly the new three-dimen-
sional imaging techniques that now become available can
improve these problems [18].
The procedure does require some form of anesthesia
and can be done under general or spinal anesthesia. While
some urologists advocate an outpatient application of
brachytherapy, generally most of the elderly patients for
whom this technique is designed [19] require a hospital
stay of 2–3 days [19]. For the procedure the patient is
placed in a lithotomy position and a transurethral catheter
should be inserted in patients with a large gland.
Posttreatment dosimetry is essential in assessing the
quality of seed implantation. CAT scanning is used to
visually identify the implanted seeds, and isodose curves
are calculated for each CT image. Problems due to post-
operative oedema especially near the prostatic apex and
due to image artefacts caused by the metallic seeds can
arise, and may partially explain the great variation that
can occur between target dosimetry and posttreatment
dosimetry [17]. Posttreatment dosimetry also allows for
secondary brachytherapy application in case of under-
dosage or large ‘cold spots’.
The side effects and complications caused by brachy-
therapy for prostate cancer are usually minimal or moder-
ate [14, 20–22]. Urethral symptoms of dysuria are the rule
rather than an exception but are mostly mild and disap-
pear within weeks or months [22]. Acute urinary retention
does occur in patients with pretreatment obstructive
symptoms and large glands due to oedema of the prostate
in 8–15%. Symptoms of proctitis occur in 1–9%, more
frequently (up to 12%) with longer follow-up, and will be
more common when the prostatic periphery is preferen-
tially loaded. Incontinence following brachytherapy is
uncommon and is seen usually only in patients that have
undergone transurethral resection before or after
brachytherapy. Erectile dysfunction after brachytherapy is
reported in 6–28% [13, 22–24] and usually increasing
with time. As with other forms of treatment for prostate
disorders, posttreatment erectile function is related to the
patient’s age and general health [25]. Severe complica-
ti ns are rare but some, such as urethrorectal fistula for-
mation [22], have been reported.
However, the evaluation of brachytherapy as a treat-
ment modality for prostate cancer will foremost depend
on its curative efficacy. The slow rate of proliferation and
t e long natural disease course of 10–15 years make the
assessment of any treatment for prostate cancer difficult.
Useful end-points of follow-up studies must not only be
overall survival but also progression-free survival and
biochemical evidence of progression-free survival. As
with EBRT, evidence of residual disease can be assessed
by posttreatment biopsies although the interpretation of
findings and their relevance can be difficult.
In short-term studies, posttreatment PSA assessment
has revealed progression-free survival for 103Pd and 125I
brachytherapy of 86, 88 and 76% [20, 21, 26]. However,
the definitions used for biochemical progression-free sur-
vival are not uniform and thus difficult to compare: PSA 
,1 ng/ml after 4 years [20], PSA ,4 ng/ml after 3 years
[21], and PSA without rise after reaching a nadir after 2
years [26]. Clearly, these figures are difficult to interpret
and will depend on pretreatment PSA as well.
Furthermore, the follow-up periods are as yet far too short
to assess long-term efficacy adequately.
As with EBRT, brachytherapy as a treatment modality
suffers from the drawback that in contrast to radical
prostatectomy, PSA-related definition of cure is uncertain.
Furthermore, PSA-persistence and even PSA progression
do not necessarily mean persistence or progression of the
p ostate cancer. However, for all raidotherapeutic treat-
ment modalities, a low PSA nadir (,0.2 ng/ml) is desir-
able and of prognostic significance [27].
Post-treatment biopsies of the prostate after
b achytherapy are not reliable in assessing curative effica-
cy. They should not be done before at least 18 to 24
months after brachytherapy have elapsed because due to
the radiation effect on the mitotic phase of carcinoma
c lls, the induced cell death will be prolonged.
Furthermore, post-radiation biopsies of the prostate are
difficult to interpret and errors can occur. For this reason
an ‘intermediary’ category with the need for later re-biop-
sies is now acknowledged when assessing post-treatment
biopsies for residual cancer after brachytherapy [13, 28].
A further caution must be added in that according to
Whitmore a negative biopsy simply signifies the absence
of proof of persistence, not necessarily cure [29]. The pos-
sibility of radiation resistance of undifferentiated or
anaplastic prostate cancer cells may be a factor contribut-
ing to the heterogeneity of results reported for brachyther-
apy [30].
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There are still very few data from long-term follow-up
on the curative efficacy of modern brachytherapy for
prostate cancer. Several groups report favourable outcome
data and claim a PSA relapse-free survival similar to that
achieved by radical surgery in similar patients [31–33].
Ragde et al. [34] reported a PSA-progression-free survival
of 79% after seven years for patients with organ-confined
(T1/T2) prostate cancer. Polascik et al. [35] contrast this
finding with a matched pair analysis showing a much
higher PSA relapse-free survival rate after seven years
following radical prostatectomy. In other studies the rela-
tive risk of a PSA progression after brachytherapy was
also found to be higher in comparison to radical prostate-
ctomy [36].
The assessment of brachytherapy in its ability to cure
prostate cancer in comparison to other treatment modali-
ties is at present not possible. Only long-term follow-up
studies of at least 10 years’ duration will be able to answer
some of the questions. Survival and progression-free sur-
vival data with a median follow-up of 18–37 months
which are available at present are not adequate information
on which definitive assessment should be based [12, 13].
In summary, although brachytherapy for prostate can-
cer is nothing new, modern brachytherapy with high-qual-
ity imaging and dosimetry offers new dimensions and
thus a treatment modality for prostate cancer that poten-
tially will achieve great importance in the treatment of
elderly patients with organ-confined or even locally
advanced tumours. However, at present we cannot with
s fety make statements about the curative efficacy of
brachytherapy for prostate cancer.
The low rate of complications and the ease of its
applicability have led some centres to a great enthusiasm
bout brachytherapy. Patients are often easily impressed
with simple procedures of low invasiveness. However, as
urologists we must be aware that at present data show a
better therapeutic efficacy for radical prostatectomy.
Thus, so far there is no proof that brachytherapy is as
effective in curing prostate cancer as radical prostatec-
tomy is. Until this proof is obtained, it should not be
assumed to be the case. Overemphasizing the benefits of
short hospital stay and low rate of complications can mis-
lead both patients and doctors since a low rate of compli-
cations reported may not necessarily be reproducible else-
where where this procedure is less frequently performed.
Until more is known from controlled studies about the
long-term efficacy and complications of brachytherapy
for prostate cancer, caution is advisable.
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